Liver spontaneous hypoattenuation on CT is an imaging biomarker of the severity of acute pancreatitis.


Journal

Diagnostic and interventional imaging
ISSN: 2211-5684
Titre abrégé: Diagn Interv Imaging
Pays: France
ID NLM: 101568499

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 10 02 2022
revised: 23 03 2022
accepted: 24 03 2022
pubmed: 3 5 2022
medline: 8 9 2022
entrez: 2 5 2022
Statut: ppublish

Résumé

The purpose of this study was to evaluate the relationship between liver spontaneous attenuation (LSA) on computed tomography (CT) reflecting the degree of steatosis, and the severity of acute pancreatitis (AP). All consecutive patients admitted from December 2014 to September 2020 for an episode of AP were retrospectively reviewed. LSA was evaluated on early CT examination and all abdominal CT examinations were reviewed by two abdominal radiologists. Severity of AP was categorized using Atlanta classification and CT severity index. Univariable and multivariable statistical analyses were performed. A total of 467 patients were included. There were 297 men and 170 women, with a mean age of 57 ± 19 (SD) years (range: 18-98 years). Among them, 236 patients (51%) had acute biliary pancreatitis, 134 (29%) had acute alcoholic pancreatitis and 97 (20%) had AP due to other etiologies. A total of 44 (9%) patients had severe AP and 423 (91%) had non severe AP. Median LSA was significantly lower in patients with severe AP (36 Hounsfield units [HU]; interquartile range [IQR]:18; 54) than in patients with non-severe AP (45 HU; IQR: 35; 51) (P < 0.001). In patients with alcoholic AP, median LSA was significantly lower in patients with severe AP (29 HU; IQR: 3; 43) than in those with non-severe AP (42 HU; IQR: 27; 50) (P = 0.022). At multivariable analysis, the third and fourth quartiles of liver spontaneous attenuation values (i.e., < 45 HU/>30 HU and < 30 HU) were independently associated with severe AP (OR, 3.23; 95% CI: 1.33-51.2; P = 0.038 and OR, 8.82; 95% CI: 1.91-69.7; P = 0.014; respectively). LSA on CT is associated with clinical severity of AP and may be used as an additional marker of disease severity.

Identifiants

pubmed: 35501284
pii: S2211-5684(22)00072-9
doi: 10.1016/j.diii.2022.03.008
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

401-407

Informations de copyright

Copyright © 2022 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no competing interest.

Auteurs

Benjamin Roussey (B)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France.

Paul Calame (P)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France; EA 4662 Nanomedicine Lab, Imagery and Therapeutics, University of Franche-Comté, 25030 Besançon, France. Electronic address: p1calame@chu-besancon.fr.

Lucie Revel (L)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France.

Thibaut Zver (T)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France.

Anhum Konan (A)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France.

Gael Piton (G)

Medical Intensive Care Unit, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France.

Stephane Koch (S)

Department of Gastroenterology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France.

Lucine Vuitton (L)

Department of Gastroenterology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France.

Eric Delabrousse (E)

Department of Radiology, University of Bourgogne Franche-Comté, CHRU Besançon, 25030 Besançon, France; EA 4662 Nanomedicine Lab, Imagery and Therapeutics, University of Franche-Comté, 25030 Besançon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH